[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337561-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337561-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","impact-of-histone-lysine-methyltransferase-suv4-20h2-on-cancer-onset-and-progression-with-therapeutic-potential","Impact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential","","Histone lysine methyltransferase SUV4-20H2 is part of the SUV4-20 homolog family and plays a critical role in regulating chromatin structure and gene expression. The enzyme generates the repressive H4K20me3 histone mark, influencing multiple cellular processes. When SUV4-20H2 activity is deregulated, chromatin dynamics become altered, driving misregulation of genes controlling the cell cycle, apoptosis, and DNA repair. Evidence links SUV4-20H2 to breast, colon, lung, renal, hepatocellular, and pancreatic malignancies, and highlights its mechanistic relevance for therapeutic targeting of epigenetic alterations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-histone-lysine-methyltransferase-suv4-20h2-on-cancer-onset-and-progression-with-therapeutic-potential/337561/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-histone-lysine-methyltransferase-suv4-20h2-on-cancer-onset-and-progression-with-therapeutic-potential/337561.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does SUV4-20H2 do at the chromatin level?","Question",{"text":63,"@type":64},"SUV4-20H2 catalyzes trimethylation of histone H4 lysine 20 to form H4K20me3, a repressive histone mark that shapes chromatin structure and gene expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can deregulated SUV4-20H2 contribute to cancer?",{"text":68,"@type":64},"Deregulated SUV4-20H2 activity is associated with altered chromatin dynamics, leading to misregulation of genes involved in cell cycle control, apoptosis, and DNA repair.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are epigenetic alterations considered promising therapeutic targets?",{"text":72,"@type":64},"Because epigenetic marks are reversible, they can be targeted through strategies aimed at enzymes that write, erase, or read epigenetic modifications during drug development.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337561,1790149788,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Review  \nImpact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential  \nStela Papadaki and Christina Piperi *  \nCitation: Papadaki, S.; Piperi, C. Impact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential. Int. J. Mol. Sci. 2024, 25, 2498. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25052498](10.3390/ijms25052498)  \nAcademic Editor: Saverio Candido  \nReceived: 26 January 2024  \nRevised: 15 February 2024  \nAccepted: 16 February 2024  \nPublished: 21 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, 11527 Athens, Greece; [stylianipapadaki@outlook.com.gr](stylianipapadaki@outlook.com.gr)  \n* Correspondence: [cpiperi@med.uoa.gr](cpiperi@med.uoa.gr); Tel.: +30-210-7462-610  \nAbstract: Histone lysine methyltransferase SUV4-20H2, a member of the suppressor of variegation 4–20 homolog (SUV4-20) family, has a critical impact on the regulation of chromatin structure and gene expression. This methyltransferase establishes the trimethylation of histone H4 lysine 20 (H4K20me3), a repressive histone mark that affects several cellular processes. Deregulated SUV4- 20H2 activity has been associated with altered chromatin dynamics, leading to the misregulation of key genes involved in cell cycle control, apoptosis and DNA repair. Emerging research evidence indicates that SUV4-20H2 acts as a potential epigenetic modifier, contributing to the development and progression of several malignancies, including breast, colon and lung cancer, as well as renal, hepatocellular and pancreatic cancer. Understanding the molecular mechanisms that underlie SUV4- 20H2-mediated effects on chromatin structure and gene expression may provide valuable insights into novel therapeutic strategies for targeting epigenetic alterations in cancer. Herein, we discuss structural and functional aspects of SUV4-20H2 in cancer onset, progression and prognosis, along with current targeting options.  \nKeywords: lysine methyltransferase; epigenome; epigenetic modifications; chromatin compaction; heterochromatin; gene regulation; histone modifications; DNA methylation; cancer  \n1. Introduction  \nCancer onset involves the deregulation of developmental and homeostatic pathways, resulting in the acquisition of certain cellular characteristics, interacting systemically to induce pathogenesis. Such traits include uncontrolled cellular proliferation, nonoxidative metabolism, metastasis and invasiveness, genomic instability, tumor-induced immune activation and resistance to growth suppressor stimuli, acquired through differential gene regulation [1] . This process can be achieved either directly, implicating transcriptional factors downstream of signaling molecules, or indirectly, through a complex network of biochemical modifications/marks established on gene bodies or regulatory areas. This set of alterations is termed the epigenome and refers to a number of reversible modifications that finetune gene expression in accordance with stimuli and time [2] . These modifications include DNA methylation, covalent and noncovalent histone modifications and the repositioning of nucleosomes and noncoding RNAs that participate in chromatin structure [3] . It is important to highlight that these alterations do not alter the DNA sequence despite the fact that some of them use it as a binding scaffold. Moreover, these alterations have different impacts on gene expression regulation, with some of them activating and others suppressing ge","cbCaifSLnwBfB1hY","https://ap.wps.com/l/cbCaifSLnwBfB1hY","pdf",1569233,22,"English","# Introduction\n## DNA Methylation: A Key Epigenetic Mechanism in Cancer","[{\"question\":\"What does SUV4-20H2 do at the chromatin level?\",\"answer\":\"SUV4-20H2 catalyzes trimethylation of histone H4 lysine 20 to form H4K20me3, a repressive histone mark that shapes chromatin structure and gene expression.\"},{\"question\":\"How can deregulated SUV4-20H2 contribute to cancer?\",\"answer\":\"Deregulated SUV4-20H2 activity is associated with altered chromatin dynamics, leading to misregulation of genes involved in cell cycle control, apoptosis, and DNA repair.\"},{\"question\":\"Why are epigenetic alterations considered promising therapeutic targets?\",\"answer\":\"Because epigenetic marks are reversible, they can be targeted through strategies aimed at enzymes that write, erase, or read epigenetic modifications during drug development.\"}]","Impact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential | PDF",1790019633,55,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50ae861098d424093814c2a8916befc8.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c7633051a7b91c137853dd0f08db25a.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef1b2e2fecf860127847c925e88c76b7.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acc16e42d9df168e8cbbc2711c0845d3.webp",980,1385]